Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
home:diseases:celiac [07.20.2019]
sallieq [recent research]
home:diseases:celiac [04.26.2020]
sallieq [recent research]
Line 75: Line 75:
 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases.  2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. 
 (({{pubmed>long:30594690}})) (({{pubmed>long:30594690}}))
 +
 +Research associated with J Tye-Din   (({{pubmed>long:    20650871}})) ,  (({{pubmed>long:17629515}})) ,  (({{pubmed>long:888}})) ,  (({{pubmed>long:    19942485}})) ,  (({{pubmed>long:23981538}})) ,  (({{pubmed>long:16099789}})) ,  (({{pubmed>long:888}})) 
 +
 +
  
 {{tag>diseases }} {{tag>diseases }}
home/diseases/celiac.txt · Last modified: 04.26.2020 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.